IP Library › Patent Application 18024159

Patent Application

App. No. 18/024,159

STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 18/024,159

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for the inhibition of Signal Transducer and Activator of Transcription 5a and 5b (STAT5). Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as, for example, breast cancer, hematological cancer, and pancreatic cancer.

Claims (203)

1 . A compound of Formula (A), or a pharmaceutically acceptable salt or solvate thereof:

wherein,

R 1 is substituted or unsubstituted phenyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted naphthyl, or substituted or unsubstituted mono- or bi-cyclic heteroaryl, wherein the mono- or bi-cyclic heteroaryl contains 1 to 4 heteroatoms selected from O, N, and S;

R 2 is substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted C 3 -C 7 heterocycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, or substituted or unsubstituted mono- or bi-cyclic heteroaryl, wherein the mono- or bi-cyclic heteroaryl contains 1 to 4 heteroatoms selected from O, N, and S;

R 3 is

wherein each of the R 31 , R 32 , R 33 , R 34 and R 35 is independently H, F, Cl, Br, or I, provided that (i) at least one of the R 31 , R 32 , R 33 , R 34 and R 35 is selected from H, Cl, Br, and I, and (ii) at least four of the R 31 , R 32 , R 33 , R 34 and R 35 are each independently selected from F, Cl, Br, and I;

R 4 is —OR 11 , —C 0-6 alkylene-R 41 , C(O)N(R 11 ) 2 , C(O)OR 11 , S(O) 2 N(R 11 ) 2 , or a carboxylic acid isostere, wherein the alkylene is substituted or unsubstituted and wherein R 41 is C(O)N(R 11 ) 2 , C(O)OR 11 , S(O) 2 N(R 11 ) 2 , or a carboxylic acid isostere;

each of R 7 and R 8 is independently selected from the group consisting of H, F, amino, —OR 11 , substituted or unsubstituted mono-C 1 -C 6 alkylamino, substituted or unsubstituted di-C 1 -C 6 alkylamino, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, and substituted or unsubstituted C 1 -C 6 heteroalkyl, or R 7 and R 8 , taken together with the carbon to which they are attached form a substituted or unsubstituted 3, 4, 5, or 6-membered ring;

each of R 5 and R 6 is independently selected from hydrogen, F, —CN, —OR 11 , —SR 1 , —N(R 11 ) 2 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, and substituted or unsubstituted C 3 -C 7 heterocycloalkyl, or R 5 and R 6 , taken together form an oxo, oxime, or with the carbon to which they are attached form a substituted or unsubstituted spirocyclic 3, 4, 5, or 6-membered ring,

wherein each of R 9 and R 10 is independently selected from the group consisting of H, F, amino, —OR 11 , substituted or unsubstituted mono-C 1 -C 6 alkylamino, substituted or unsubstituted di-Cr C 6 alkylamino, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, and substituted or unsubstituted C 1 -C 6 heteroalkyl, or R 9 and R 10 , taken together with the carbon to which they are attached form a substituted or unsubstituted 3, 4, 5, or 6-membered ring; or

R 5 and R 9 , taken together with the intervening atoms to which they are attached form a 4, 5 or 6-membered ring,

wherein R 6 is selected from hydrogen, F, —CN, —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(═O)R 11 , —C(═O)R 11 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, and substituted or unsubstituted C 3 -C 7 heterocycloalkyl,

wherein R 10 is selected from the group consisting of H, F, amino, —OR 11 , substituted or unsubstituted mono-C 1 -C 6 alkylamino, substituted or unsubstituted di-C 1 -C 6 alkylamino, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, and substituted or unsubstituted C 1 -C 6 heteroalkyl, wherein the alkyl, haloalkyl or heteroalkyl is optionally substituted with hydroxy, amino, or methoxy,

provided that p is 1 and q is 1;

each of R B is independently halogen, —CN, —NO 2 , —OR 11 , —SR 11 , —N(R 11 ) 2 , —NR 11 S(═O) 2 R 11 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2 -C 6 alkynyl, substituted or unsubstituted —C 0-6 alkylene-C 3-8 cycloalkyl, or substituted or unsubstituted —C 0-6 alkylene-C 3-7 heterocycloalkyl;

X is O, NR 11 , or absent;

each R 11 is independently H, substituted or unsubstituted d C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2 -C 6 alkynyl, substituted or unsubstituted —C 0-6 alkylene-C 3-8 cycloalkyl, or substituted or unsubstituted —C 0-6 alkylene-C 3-7 heterocycloalkyl;

each of n and q is independently 0, 1, 2, or 3;

p is 1, 2, or 3; and

m is 1, 2, 3, or 4.

2 . The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has a structure of Formula (I):

wherein,

R 11 is substituted or unsubstituted phenyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted naphthyl, or substituted or unsubstituted mono- or bi-cyclic heteroaryl, wherein the mono- or bi-cyclic heteroaryl contains 1 to 4 heteroatoms selected from O, N, and S;

R 3 is

each of R 5 and R 6 is independently selected from hydrogen, F, —CN, —OR 11 , —SR 11 , —N(R 11 ) 2 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, and substituted or unsubstituted C 3 -C 7 heterocycloalkyl, or R 5 and R 6 , taken together form an oxo, oxime, or with the carbon to which they are attached form a substituted or unsubstituted spirocyclic 3, 4, 5, or 6-membered ring,

wherein each of R 9 and R 10 is independently selected from the group consisting of H, F, amino, —OR 11 , substituted or unsubstituted mono-C 1 -C 6 alkylamino, substituted or unsubstituted di-C 1 -C 6 alkylamino, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, and substituted or unsubstituted C 1 -C 6 heteroalkyl, or R 9 and R 10 , taken together with the carbon to which they are attached form a substituted or unsubstituted 3, 4, 5, or 6-membered ring; or

R 5 and R 9 , taken together with the intervening atoms to which they are attached form a 4, 5 or 6-membered ring,

wherein R 6 is selected from hydrogen, F, —CN, —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(═O)R 1 , —C(═O)R 11 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, and substituted or unsubstituted C 3 -C 7 heterocycloalkyl,

provided that p is 1 and q is 1;

each of R B and R B1 is independently halogen, —CN, —NO 2 , —OR 11 , —SR 11 , —N(R 11 ) 2 , —NR 11 S(═O) 2 R 11 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2 -C 6 alkynyl, substituted or unsubstituted —C 0-6 alkylene-C 3-8 cycloalkyl, or substituted or unsubstituted —C 0-6 alkylene-C 3-7 heterocycloalkyl;

X is O, NR 11 , or absent;

each R 11 is independently H, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2 -C 6 alkynyl, substituted or unsubstituted C 1 -C 6 haloalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted —C 0-6 alkylene-C 3-8 cycloalkyl, or substituted or unsubstituted —C 0-6 alkylene-C 3-7 heterocycloalkyl;

each of n and q is independently 0, 1, 2, or 3;

p is 1, 2, or 3; and

m is 0, 1, 2, or 3.

3 . The compound or salt of claim 1 or 2 , wherein the substituted versions of C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 heteroalkyl, mono-C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, C 2-6 alkenyl, C 2 -C 6 alkynyl, —C 0-6 alkylene are each optionally substituted with one or more substituents independently selected from: halogen, —OR 12 , —SR 12 , —N(R 12 ) 2 , —C(O)R 12 , —C(O)OR 12 , —OC(O)R 12 , —OC(O)N(R 12 ) 2 , —C(O)N(R 12 ) 2 , —N(R 12 )C(O)R 12 , —N(R 12 )C(O)OR 12 , —N(R 12 )C(O)N(R 12 ) 2 , —N(R 12 ) 2 S(O) 2 (R 12 ), —S(O)R 12 , —S(O) 2 R 12 , —S(O) 2 N(R 12 ) 2 , —NO 2 , ═O, or —CN;

wherein the substituted versions of C 3 -C 8 cycloalkyl and C 3 -C 7 heterocycloalkyl are each optionally substituted with one or more substituents independently selected from: halogen, —OR 12 , —SR 12 , —N(R 12 ) 2 , —C(O)R 12 , —C(O)OR 12 , —OC(O)R 12 , —OC(O)N(R 12 ) 2 , —C(O)N(R 12 ) 2 , —N(R 12 )C(O)R 12 , —N(R 12 )C(O)OR 12 , —N(R 12 )C(O)N(R 12 ) 2 , —N(R 12 ) 2 S(O) 2 (R 12 ), —S(O)R 12 , —S(O) 2 R 12 , —S(O) 2 N(R 12 ) 2 , —NO 2 , ═O, or —CN;

wherein the substituted versions of phenyl, naphthyl, mono- or bi-cyclic heteroaryl are each optionally substituted with one or more substituents independently selected from: halogen, —OR 12 , —SR 12 , —N(R 12 ) 2 , —C(O)R 12 , —C(O)OR 12 , —OC(O)R 12 , —OC(O)N(R 12 ) 2 , —C(O)N(R 12 ) 2 , —N(R 12 )C(O)R 12 , —N(R 12 )C(O)OR 12 , —N(R 12 )C(O)N(R 12 ) 2 , —N(R 12 ) 2 S(O) 2 (R 12 ), —S(O)R 12 , —S(O) 2 R 12 , —S(O) 2 N(R 12 ) 2 , —NO 2 , ═O, —CN, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl and C 3 -C 8 cycloalkyl; and

wherein each R 12 are independently selected from hydrogen, halogen, —OH, —NO 2 , —CN, C 1-6 alkyl, C 1-6 haloalkyl, and C 3-6 carbocycle, 3- to 6-membered heterocycle, wherein the C 3-6 carbocycle and 3- to 6-membered heterocycle is optionally substituted with one or more substituents independently selected from halogen, —OH, —NO 2 , —CN, C 1-6 alkyl, C 1-6 alkoxy, and C 1-6 haloalkyl.

4 . The compound or salt of claim 3 , wherein the substituted versions of C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 heteroalkyl, mono-C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, C 2-6 alkenyl, C 2 -C 6 alkynyl, —C 0-6 alkylene are each optionally substituted with one or more substituents independently selected from: halogen, —OR 12 , —SR 12 , —N(R 12 ) 2 , —C(O)R 12 , —C(O)OR 12 , —OC(O)R 12 , —NO 2 , ═O, or —CN;

5 . The compound or salt of claim 4 , wherein when R 11 is substituted phenyl, substituents are independently selected at each occurrence from halogen, —OR 12 , —SR 12 , —N(R 12 ) 2 , —C(O)R 12 , —C(O)OR 12 , —NO 2 , ═O, —CN, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl and C 3 -C 8 cycloalkyl.

6 . The compound of claim 4 or 5 , wherein when R 2 is substituted phenyl, substituents are independently selected at each occurrence from halogen, —OR 12 , —SR 12 , —N(R 12 ) 2 , —C(O)R 12 , —C(O)OR 12 , —NO 2 , ═O, —CN, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl and C 3 -C 8 cycloalkyl.

7 . The compound or salt of any one of claims 1 to 6 , or a pharmaceutically acceptable salt or solvate thereof, wherein each R 6 is independently selected from H, F, methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, —CF 3 , —CH 2 CF 3 , —CH 2 CH 2 F, —OCF 3 , —OH, —OCH 3 , —OCH 2 CH 3 , —OCH 2 OMe, and —OCH 2 CH 2 OH.

8 . The compound or salt of any one of claims 1 to 7 , or a pharmaceutically acceptable salt or solvate thereof, wherein each R 6 is H.

9 . The compound of any one of claims 1 to 8 , wherein X is O.

10 . The compound of claim 1 or 2 , or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has a structure of Formula (II):

wherein,

R 3 is

each of R 7 and R 8 is independently selected from the group consisting of H, F, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, and substituted or unsubstituted C 1 -C 6 heteroalkyl, or R 7 and R 8 , taken together with the carbon to which they are attached form a substituted or unsubstituted 3, 4, 5, or 6-membered ring;

R 5 is selected from hydrogen, F, —CN, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, and substituted or unsubstituted C 3 -C 7 heterocycloalkyl,

wherein each of R 9 and R 10 is independently selected from the group consisting of H, F, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, and substituted or unsubstituted C 1 -C 6 heteroalkyl, or R 9 and R 10 , taken together with the carbon to which they are attached form a substituted or unsubstituted 3, 4, 5, or 6-membered ring; or

R 5 and R 9 , taken together with the intervening atoms to which they are attached form a 4, 5 or 6-membered ring, and R 10 is selected from the group consisting of H, F, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, and substituted or unsubstituted C 1 -C 6 heteroalkyl, wherein the alkyl, haloalkyl or heteroalkyl is optionally substituted with hydroxy, amino, or methoxy;

m is 0, 1, 2, or 3.

11 . The compound of any one of claims 1 to 10 , or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has a structure of Formula (IIa):

wherein,

R 3 is

m is 0, 1, 2, or 3.

12 . The compound of claim 1 to 10 , or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has a structure of Formula (IIb):

wherein,

R 3 is

each R 11 is independently H, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted —C 0-6 alkylene-C 3-8 cycloalkyl, or substituted or unsubstituted —C 0-6 alkylene-C 3-7 heterocycloalkyl;

m is 0, 1, 2, or 3.

13 . The compound of any one of claims 1 to 12 , or a pharmaceutically acceptable salt or solvate thereof, wherein each of R 5 is independently H, methyl, ethyl, propyl, butyl, pentyl, or hexyl, wherein the methyl, ethyl, propyl, butyl, pentyl, or hexyl is linear or branched, substituted or unsubstituted.

14 . The compound of any one of claims 1 to 13 , or a pharmaceutically acceptable salt or solvate thereof, wherein each of R 7 , R 8 , R 9 , and R 10 is independently selected from the group consisting of H, F, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 fluoroalkyl, and substituted or unsubstituted C 1 -C 6 heteroalkyl, wherein the alkyl, fluoroalkyl or heteroalkyl is optionally substituted with hydroxy, amino, or methoxy.

15 . The compound of any one of claims 1 to 14 , or a pharmaceutically acceptable salt or solvate thereof, wherein each of R 7 , R 8 , R 9 , and R 10 is H.

16 . The compound of claim 1 or 2 , or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has a structure of Formula (III):

wherein,

R 3 is

m is 0, 1, 2, or 3.

17 . The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein

and wherein each of R B1 , R B2 , R B3 , and R B4 is independently H or R B .

18 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is halogen.

19 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is a linear or branched, substituted or unsubstituted C 1 -C 6 alkyl.

20 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, linear or branched pentyl, linear or branched hexyl, —CF 3 , —CH 2 NH 2 , —CH 2 CF 3 , —CH 2 CHNH 2 , —CH 2 CH 2 F, —CH 2 OH, or —CH 2 CH 2 OH.

21 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2 -C 6 alkynyl, substituted or unsubstituted —C 0-3 alkylene-C 3-8 cycloalkyl, or substituted or unsubstituted —C 0-3 alkylene-C 3-7 heterocycloalkyl.

22 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is C 3-6 cycloalkyl, —CH 2 —C 3-6 cycloalkyl, —(CH 2 ) 2 —C 3-6 cycloalkyl, —(CH 2 ) 3 —C 3-6 cycloalkyl, C 3-5 heterocycloalkyl, —CH 2 —C 3-5 heterocycloalkyl, —(CH 2 ) 2 —C 3-5 heterocycloalkyl, or —(CH 2 ) 3 —C 3-5 heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl is substituted or unsubstituted.

23 . The compound of claim 21 or 22 , or a pharmaceutically acceptable salt or solvate thereof, wherein the cycloalkyl or heterocycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein the cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl is optionally substituted; and wherein 0 to 2 of the ring carbon atoms are optionally and independently replaced by nitrogen, oxygen and sulfur.

24 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is

25 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is

26 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is —OR 11 .

27 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is OH.

28 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is substituted or unsubstituted —O—C 1 -C 6 alkyl.

29 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is

30 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is substituted or unsubstituted —O—C 0-6 alkylene-C 3-8 cycloalkyl, or substituted or unsubstituted —O—C 0-6 alkylene-C 3-7 heterocycloalkyl.

31 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is

32 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is

33 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is

34 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is —N(R 11 ) 2 .

35 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein R B1 is —N(CH 3 ) 2 , —NHCH 3 , —N(CH 2 CH 3 ) 2 , —NHCH 2 CH 3 , or —N(CH 2 CH 2 CH 3 ) 2 .

36 . The compound of any one of claims 2 to 35 , or a pharmaceutically acceptable salt or solvate thereof, wherein m is 0 or 1.

37 . The compound of any one of claims 1 to 36 , or a pharmaceutically acceptable salt or solvate thereof, wherein each R B is independently halogen, —CN, —OR 11 , —SR 11 , —N(R 11 ) 2 , —NR 11 S(═O) 2 R 11 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted —C 0-3 alkylene-C 3-6 cycloalkyl, or substituted or unsubstituted —C 0-3 alkylene-C 3-5 heterocycloalkyl.

38 . The compound of any one of claims 1 to 36 , or a pharmaceutically acceptable salt or solvate thereof, wherein each R B is independently linear or branched, substituted or unsubstituted C 1 -C 6 alkyl.

39 . The compound of claim 38 , or a pharmaceutically acceptable salt or solvate thereof, wherein each C 1 -C 6 alkyl is independently methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, linear or branched pentyl, linear or branched hexyl, —CF 3 , —CH 2 NH 2 , —CH 2 CF 3 , —CH 2 CHNH 2 , —CH 2 CH 2 F, —CH 2 OH, or —CH 2 CH 2 OH.

40 . The compound of any one of claims 1 to 36 , or a pharmaceutically acceptable salt or solvate thereof, wherein each of R B is independently substituted or unsubstituted —C 0-6 alkylene-C 3-8 cycloalkyl, or substituted or unsubstituted —C 0-6 alkylene-C 3-7 heterocycloalkyl.

41 . The compound of any one of claims 1 to 36 , or a pharmaceutically acceptable salt or solvate thereof, wherein each of R B is independently C 3-6 cycloalkyl, —CH 2 —C 3-6 cycloalkyl, —(CH 2 ) 2 —C 3-6 cycloalkyl, —(CH 2 ) 3 —C 3-6 cycloalkyl, C 3-5 heterocycloalkyl, —CH 2 —C 3-5 heterocycloalkyl, —(CH 2 ) 2 —C 3-5 heterocycloalkyl, or —(CH 2 ) 3 —C 3-5 heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl is substituted or unsubstituted.

42 . The compound of any one of claims 40 to 41 , wherein the cycloalkyl or heterocycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein the cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl is optionally substituted; and wherein 0 to 2 of the ring carbon atoms are optionally and independently replaced by nitrogen, oxygen and sulfur.

43 . The compound of any one of claims 40 to 42 , wherein each of the cycloalkyl is independently

44 . The compound of any one of claims 40 to 42 , wherein each of the heterocycloalkyl is independently

45 . The compound of any one of claims 1 to 36 , or a pharmaceutically acceptable salt or solvate thereof, wherein each R B is independently —OR 11 .

46 . The compound of claim 45 , wherein each —OR 11 is independently OH, —O—C 1 -C 6 alkyl, —O—C 1 -C 6 haloalkyl, —O—C 1 -C 6 heteroalkyl, —O—C 0-6 alkylene-C 3-8 cycloalkyl, or —O—C 0-6 alkylene-C 3-7 heterocycloalkyl, wherein the alkyl, haloalkyl, heteroalkyl, cycloalkyl, and heterocycloalkyl is substituted or unsubstituted.

47 . The compound of any one of claims 1 to 36 , or a pharmaceutically acceptable salt or solvate thereof, wherein each R B is independently substituted or unsubstituted —C 1 -C 6 alkyl.

48 . The compound of any one of claims 1 to 36 , or a pharmaceutically acceptable salt or solvate thereof, wherein each R B is independently

49 . The compound of any one of claims 1 to 36 , or a pharmaceutically acceptable salt or solvate thereof, wherein each R B is OH.

50 . The compound of any one of claims 1 to 36 , or a pharmaceutically acceptable salt or solvate thereof, wherein each R B is independently substituted or unsubstituted —O—C 0-6 alkylene-C 3-8 cycloalkyl, or substituted or unsubstituted —O—C 0-6 alkylene-C 3-7 heterocycloalkyl.

51 . The compound of any one of claims 1 to 36 , or a pharmaceutically acceptable salt or solvate thereof, wherein each R B is independently

52 . The compound of any one of claims 1 to 36 , or a pharmaceutically acceptable salt or solvate thereof, wherein each R B is independently —N(R 11 ) 2 .

53 . The compound of any one of claims 1 to 36 , or a pharmaceutically acceptable salt or solvate thereof, wherein each R B is independently —N(CH 3 ) 2 , —NHCH 3 , —N(CH 2 CH 3 ) 2 , —NHCH 2 CH 3 , or —N(CH 2 CH 2 CH 3 ) 2 .

54 . The compound of any one of claims 1 to 53 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 is COOH.

55 . The compound of any one of claims 1 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein

56 . The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein

57 . The compound of any one of claims 2 to 17 , or a pharmaceutically acceptable salt or solvate thereof, wherein

58 . The compound of any one of claims 1 to 57 , R 11 is substituted or unsubstituted phenyl, substituted or unsubstituted C 3 -C 8 cycloalkyl, substituted or unsubstituted naphthyl, or substituted or unsubstituted mono- or bi-cyclic heteroaryl, wherein the mono- or bi-cyclic heteroaryl contains 1 to 4 heteroatoms selected from O, N, and S.

59 . The compound of any one of claims 1 to 58 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is substituted or unsubstituted phenyl.

60 . The compound of claim 58 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 11 is substituted phenyl, and wherein the phenyl is substituted with 1 to 5 substituents independently selected from halogen, —CN, —NO 2 , —OR 11 , —N(R 11 ) 2 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, substituted or unsubstituted —C 0-6 alkylene-C 3-8 cycloalkyl, and substituted or unsubstituted —C 0-6 alkylene-C 3-7 heterocycloalkyl.

61 . The compound of claim 58 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 11 is substituted phenyl, and wherein the phenyl is substituted with one or two C 1 -C 6 alkyl, and wherein the alkyl is linear or branched, substituted or unsubstituted.

62 . The compound of claim 58 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 11 is substituted phenyl, and wherein the phenyl is substituted with one or two C 3-8 cycloalkyl, and wherein the cycloalkyl is substituted or unsubstituted.

63 . The compound of claim 58 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 11 is substituted phenyl, wherein the phenyl is substituted with one C 3-8 cycloalkyl and one C 1 -C 6 alkyl, and wherein the cycloalkyl and alkyl is substituted or unsubstituted.

64 . The compound of claim 58 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 11 is substituted phenyl, wherein the phenyl is substituted with 1, 2, or 3 R A , and wherein each R A is independently halogen, —CN, —NO 2 , —OR 11 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, substituted or unsubstituted —C 0-6 alkylene-C 3-8 cycloalkyl, or substituted or unsubstituted —C 0-6 alkylene-C 3-7 heterocycloalkyl, or wherein two R A , taken together with the intervening atoms to which they are attached form a 4, 5, or 6 membered ring.

65 . The compound of claim 64 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 1

66 . The compound of claim 58 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is

and wherein each R A is independently H, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 alkoxy, substituted or unsubstituted C 3 -C 6 cycloalkyl, or substituted or unsubstituted C 3 -C 6 heterocycloalkyl.

67 . The compound of claim 58 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is

and wherein each R A is independently selected from H, t-butyl, —OCH(CH 3 ) 2 , cyclopropyl, and pyrrolidinyl.

68 . The compound of claim 58 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is

69 . The compound of claim 58 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is

70 . The compound of any one of claims 1 to 57 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is substituted or unsubstituted monocyclic heteroaryl containing 1, 2, or 3 nitrogen(s).

71 . The compound of claim 70 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 11 is substituted or unsubstituted pyridinyl, pyridazinyl, or pyrimidinyl.

72 . The compound of any one of claims 1 to 57 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is substituted or unsubstituted 5-6, 6-6, or 6-5 fused bicyclic heteroaryl containing 1-3 hetero ring atoms selected from O, N and S.

73 . The compound of any one of claims 1 to 72 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is phenyl or substituted phenyl.

74 . The compound of claim 73 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is phenyl substituted with 1 to 5 R C , and wherein each R C is independently halogen, —OR 11 , —SR 11 , —N(R 11 ) 2 , —CN, —NO 2 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted —C 0-6 alkylene-C 3-8 cycloalkyl, or substituted or unsubstituted —C 0-6 alkylene-C 3-7 heterocycloalkyl.

75 . The compound of claim 73 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is phenyl substituted with 1 to 5 R C , and wherein each R C is independently F, Cl, Br, —CN, OH, methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, —CF 3 , —CH 2 CF 3 , —CH 2 CH 2 F, —OCF 3 , —OH, —OCH 3 , —OCH 2 CH 3 , —OCH 2 OMe, —OCH 2 CH 2 OH, —OC(CH 3 ) 3 , —OCH 2 CH 2 OCH 3 ,

76 . The compound of claim 74 or 75 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is

and wherein each of R C1 , R C2 , R C3 , R C4 , and R C5 is independently H or R C .

77 . The compound of any one of claims 1 to 72 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is substituted or unsubstituted 5-membered or 6-membered monocyclic heteroaryl.

78 . The compound of claim 77 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is pyridinyl, pyridazinyl, pyrimidinyl, triazinyl, wherein the pyridinyl, pyridazinyl, pyrimidinyl, or triazinyl is substituted with 1 to 4 R C , and wherein each R C is independently halogen, —OR 11 , —SR 11 , —N(R 11 ) 2 , —CN, —NO 2 , substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 1 -C 6 haloalkyl, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted —C 0-6 alkylene-C 3-8 cycloalkyl, or substituted or unsubstituted —C 0-6 alkylene-C 3-7 heterocycloalkyl.

79 . The compound of claim 78 , or a pharmaceutically acceptable salt or solvate thereof, wherein each R C is independently F, Cl, Br, —CN, OH, methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, —CF 3 , —CH 2 CF 3 , —CH 2 CH 2 F, —OCF 3 , —OH, —OCH 3 , —OCH 2 CH 3 , —OCH 2 OMe, —OCH 2 CH 2 OH, —OC(CH 3 ) 3 , —OCH 2 CH 2 OCH 3

80 . The compound of claim 78 or 79 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is

and wherein each of R C1 , R C2 , R C3 , and R C5 is independently H or R C .

81 . The compound of any one of claims 1 to 72 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is

82 . The compound of any one of claims 1 to 72 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is

83 . The compound of any one of claims 1 to 72 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is

84 . The compound of any one of claims 1 to 72 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is substituted or unsubstituted bicyclic C 5 -C 8 cycloalkyl.

85 . The compound of any one of claims 1 to 84 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 31 is H, F, Cl, or Br.

86 . The compound of any one of claims 1 to 84 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 32 is H, F, Cl, or Br.

87 . The compound of any one of claims 1 to 84 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 33 is H, F, Cl, or Br.

88 . The compound of any one of claims 1 to 84 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 34 is H, F, Cl, or Br.

89 . The compound of any one of claims 1 to 84 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 35 is H, F, Cl, or Br.

90 . The compound of any one of claims 1 to 84 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is

91 . The compound of any one of claims 1 to 84 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is

92 . The compound of any one of claims 1 to 84 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is

93 . A compound or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is selected from a compound of Table 1.

94 . The compound of any one of claims 1 to 93 , or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has an IC50 value of at most 6 μM, at most 1.2 μM, at most 0.4 μM, or at most 100 nM as measured in a MV4-11 cell cytotoxicity assay.

95 . The compound of any one of claims 1 to 93 , or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has an IC50 value of at most 0.4 μM as measured in a MV4-11 cell cytotoxicity assay.

96 . The compound of any one of claims 1 to 95 , or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has an t ½ value of at least 1275 minutes, at least 800 minutes, at least 500 minutes, at least 300 minutes, at least 275 minutes, at least 250 minutes, or at least 100 minutes as measured in by High-performance liquid chromatography (HPLC) in a reactivity profiling assay with glutathione.

97 . The compound of any one of claims 1 to 96 , or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has an t ½ value of at least 250 minutes as measured in by HPLC in a reactivity profiling assay with glutathione.

98 . The compound of any one of claims 1 to 97 , or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has an IC50 value of at least 24.0 μM, at least 12.0 μM, at least 2.5 μM, or at least 2.0 μM as measured in a NHF cytotoxicity assay.

99 . The compound of any one of claims 1 to 97 , wherein the compound has an IC50 value of at least 24.0 μM as measured in a NHF cell cytotoxicity assay.

100 . A pharmaceutical composition comprising a compound of any one of claims 1 to 99 , or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient or carrier.

101 . A method of modulating signal transducer and activator of transcription 5a and 5b (STAT5) proteins in a subject in need thereof, comprising

administering to a subject a therapeutically effective amount of the compound of any one of claims 1 to 99 , or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition of claim 100 .

102 . The method of claim 101 , wherein the subject has cancer.

103 . A method of treating cancer in a subject in need thereof, comprising administering to a subject with cancer a therapeutically effective amount of the compound of any one of claims 1 to 99 , or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition of claim 100 .

104 . The method of claim 102 or 103 , wherein the cancer is a solid tumor or hematological cancer.

105 . The method of claim 102 or 103 , wherein the cancer is breast cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, hepatocellular cancer, colorectal cancer, gastric adenocarcinoma, melanoma, or advanced cancer.

Assignments (4)

RELEASE OF SECURITY INTEREST Recorded Jun 24, 2026

From: OXFORD FINANCE LLC

To: CENTESSA PHARMACEUTICALS (UK) LIMITED

Reel/Frame 075069/0879 →

SECURITY INTEREST Recorded Dec 31, 2024

From: CENTESSA PHARMACEUTICALS (UK) LIMITED

To: OXFORD FINANCE LLC

Reel/Frame 069708/0039 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2023

From: JANPIX LIMITED

To: CENTESSA PHARMACEUTICALS (UK) LIMITED

Reel/Frame 065695/0341 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2023

From: FLECK, ROMAN; PROUDFOOT, JOHN; OMEARA, JEFF; GUNNING, PATRICK THOMAS; ALI, AHMED MAGDY; ROSA, DAVID ALEXANDER; PALERM, ANGEL SAMPEDRO; DARWISH, ALLA; JOHN, ALFORD ANTOINE

To: JANPIX LIMITED

Reel/Frame 063659/0361 →